Domain 1 Pharmacokinetic and pharmacodynamics properties of methadone

Similar documents
Maximizing Safety and Efficacy in Methadone Dosing Among Hospice Patients. Introduction

Mitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly

Palliative and Hospice Care of the Terminally Ill Introduction

Overview of Essentials of Pain Management. Updated 11/2016

Dose equivalent of fentanyl patch to oxycontin

What Do You Mean The Morphine Isn t Working? Objectives. Opioid Epidemic. Ellen Fulp, PharmD, BCGP Clinical Education Coordinator AvaCare, Inc.

Opioid Pearls and Acute Pain Management

Opioid Conversions Mixture of Science and Art

Fighting the Good Fight: How to Convert Opioids Just Right!

CHAMP: Bedside Teaching TREATING PAIN. Stacie Levine MD. What is the approach to treating pain in the aging adult patient?

Analgesics: Management of Pain In the Elderly Handout Package

Prior Authorization for Opioid Products Indicated for Pain Management

What Hospice Providers Want to Know about Medical Cannabis

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

Pain Management in the

To Infinity and Beyond! Safe and Effective Opioid Titration Strategies

Update on Pain: Collaborative Care for the Complex Patient

1/21/14. Cancer Related Pain: Case-Based Pharmacology. Conflicts of Interest. Learning Objective

CHRONIC PAIN MANAGEMENT

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids

Pain Management in Medical Dermatology

Acute Pain Management in the Hospital Setting. Alexandra Phan, PharmD PGY-1 Pharmacy Practice Resident Medical Center Hospital Odessa, TX

You Scream, I Scream, We All Scream for Morphine! Key Opioid Issues in Contemporary Hospice Practice

PAIN MANAGEMENT DISCHARGE COMMUNICATION (PM-DC) AUDIT TOOL

Pain: What You Need to Know to Advocate

PALLIATIVE TREATMENT BY DR. KHRONGKAMOL SIHABAN MEDICAL ONCOLOGIST

ANSWER # 1 PHARMACOLOGY. Methadone answers Stoltzfus 4/5/2012 METHADONE: WHY GRANDMA S TAKING A DIPHENYLHEPTANE (ANSWERS) JANUARY 26, 2017

4/3/2018. Management of Acute Pain Crises. Five Mistakes I ve made and why you shouldn t

Long Term Care Formulary HCD - 08

PAIN MANAGEMENT PGY-1. Aaron D. Storms, MD Carin van Zyl, MD Adult and Pediatric Palliative Care, LAC+USC Keck School of Medicine of USC

10 mg hydrocodone equals how much oxycodone

Oxycontin to ms contin conversion chart

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

Jim McGregor MD. What s New in Pain and Symptom Management. CAHSAH CHAPCA Annual Conference & Expo May 22 24, 2018, Monterey, CA

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

Pain Management in Medical Dermatology

Pain and the MGH Promise

CLINICAL POLICY DEPARTMENT: Medical

Methadone Maintenance

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

Rule Governing the Prescribing of Opioids for Pain

Blueprint for Prescriber Continuing Education Program

Pain Management Strategies Webinar/Teleconference

E-Learning Module N: Pharmacological Review

Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans

Pain Management Wrap-Up Chronic Care. David Tauben, MD Medicine Anesthesia & Pain Medicine

Arresting Pain without Getting Arrested

PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

Lumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes.

SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)

Prior Authorization Guideline

Slide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists

Non-opioid and adjuvant pain management

Oral Pain Medications in Your Practice Scot Morris, OD, FAAO

Appropriate prescribing of Oxycodone for non-cancer pain in general practice

Use of PCA devices in Difficult Populations

Opioid Case Studies. Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN. September 29, MFMER slide-1

GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)

B. Long-acting/Extended-release Opioids

PALLIATIVE CARE PRESCRIBING FOR PATIENTS WHO ARE SUBSTANCE MISUSERS

WR Fentanyl Symposium. Opioids, Overdose, and Fentanyls

UCSF PAIN SUMMIT /8/15

Pain Management: The Use of Methadone in Hospice and Palliative Care. By: Kiran Hamid, RPh August 16, 2018.

Amber D. Hartman, PharmD Specialty Practice Pharmacist James Cancer Center & Solove Research Institute Ohio State University Medical Center

Care of the Dying Management in Severe Renal Failure

Learning Objectives. Perioperative goals. Acute Pain in the Chronic Pain Patient for Ambulatory Surgery 9/8/16

Objectives. What is pain? 9/27/2017. Pain: Does this Hurt? Fall 2017 Dean Fox, MD, FACP

PERIOPERATIVE PAIN MANAGEMENT: WHAT S UP WITH METHADONE?

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care

Disclosures. Management of Chronic, Non- Terminal Pain. Learning Objectives. Outline. Drug Schedules. Applicable State Laws

PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

Knock Out Opioid Abuse in New Jersey:

Long-Acting Opioid Analgesics

Long-Acting Opioid Analgesics

Managing Pain in Individuals with Serious Illness and Comorbid Substance Use Disorder

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR

OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM

STARSHIP WITHDRAWAL OF ANALGESIA AND SEDATION

eappendix A. Opioids and Nonsteroidal Anti-Inflammatory Drugs

Cancer patients at End-of-Life: Multidimensional Pain Requiring Multimodal Therapy

Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu

Disclosures. Ms. Walsh has nothing to disclose Ms. Broglio is on the speaker s bureau for Genentech and Meda Pharmaceuticals

Interprofessional Webinar Series

Review of Pain Management with Clinical and Regulatory Updates

Disclosure. Objectives. Houston we have a problem! The epidemic of non medical use of prescription opioids. It all started with an observation

Opioid Conversion Guidelines

See Important Reminder at the end of this policy for important regulatory and legal information.

Opioid Use in Serious Illness

RELIEVING VIRGINIA S PAIN AND SUFFERING 3:45-4:45PM

BASICS OF OPIOID PRESCRIBING 10:30-11:45AM

Clinical Trial Results with OROS Ò Hydromorphone

Transdermal and Parenteral Fentanyl Dosage Calculations and Conversions

POST OPERATIVE PAIN MANAGEMENT: PAIN AND COMPLICATIONS

Buprenorphine Access in California

OP01 [Mar96] With regards to pethidine s physical properties: A. It has an octanol coefficient of 10 B. It has a pka of 8.4

Index. E Elderly. See also Older patients analgesic efficacy and opioid adverse effects, 280

Overcoming challenges in pain management in older patients. David Lussier, MD, FRCP(c) March 21, 2012

PAIN PODCAST SHOW NOTES:

Transcription:

Methadone Survey Knowledge Domains: Domain 1 Pharmacokinetic and pharmacodynamics properties of methadone Domain 2 Appropriate/inappropriate candidates for methadone Domain 3 Risk stratification with methadone Domain 4 Drug interactions with methadone Domain 5 Dosing in opioid naïve patients Domain 6 Dosing in opioid tolerant patients Domain 7 Monitoring and education FIRST THINGS FIRST! In preparation for preparing an online learning activity on methadone dosing and monitoring for prescribers, we would like to conduct this educational needs assessment. Please complete this survey that collects demographic information, and serves as a baseline to assess knowledge, skills and attitudes regarding content that will be covered in the All results from this survey will be reported in aggregate only, and cannot be tracked to any individual participant. If you have any questions about this, please contact Dr. Mary Lynn McPherson at mmcphers@rx.umaryland.edu (or on your email system). 1. What is your discipline? a. Physician b. Advanced practice nurse c. Physician assistant 2. How long have you been licensed? a. Less than 3 years b. Three to five years c. Six to ten years d. Eleven to twenty years e. More than twenty years 3. How long have you practice in hospice/palliative medicine? a. Less than 3 years b. Three to five years c. Six to ten years

d. Eleven to twenty years e. More than twenty years 4. Are you board certified in palliative care? a. Yes b. No 5. Are you certified as a Hospice Medical Director? a. Yes b. No c. NA 6. Which of the following best describes your level of interest in using methadone to treat pain in patients with an advanced illness? (Gen) a. Very interested; it should be one of our first line opioid options interested; may be used second or third line, or in difficult cases interested; burdens (risk to patient; dosing and monitoring) exceed benefits of therapy 7. How accurately are you able to list, explain, and apply the pharmacokinetic and pharmacodynamic characteristics of methadone? (D1 skills) 8. Which of the following is a true statement regarding the use of methadone? Select all that apply. (D2 knowledge) a. Methadone may be used in patients with a true morphine/phenanthrene allergy b. Methadone may be used in patients with significant renal impairment c. Methadone should not be started in a patient within a week of death d. Methadone does not cause opioid induced adverse effects as severely as other opioids

9. List three medications known to be strong inhibitors of methadone metabolism. (D4 knowledge) a. Open answer 10. How important do you believe it is for you to be able to list, explain and apply the pharmacokinetic and pharmacodynamic characteristics of methadone? (D1 attitudes) important 11. How skillfully are you able to recommend a monitoring plan and education for patients starting methadone therapy? (D7 skills) 12. How accurately can you identify medications that may cause a clinically significant drug interaction with methadone? (D4 skills) 13. How important do you believe it is for you to be able to determine a starting dose of methadone in an opioid naïve patient? (D5 attitude) important 14. Which electrolyte abnormalities increase the risk of toxicity from methadone? Select all that apply. (D3 knowledge) a. Hyperkalemia b. Hypokalemia c. Hypermagnesemia d. Hypomagnesmia e. Hyponatremia

15. How accurately are you able to perform risk stratification for starting methadone in a patient with advanced illness? (D3 skills) 16. How important do you believe it is for you to be able to identify medications that may cause a clinically significant drug interaction with methadone? (D4 attitude) important 17. How often and for how long should the health care team assess the patient s response when starting methadone therapy (both therapeutic response and potential toxicity)? (D7 knowledge). 18. How important do you believe it is for you to be able to determine a monitoring plan and education for patients/families/caregivers when introducing methadone? (D7 attitude) important 19. Which of the following best represents the average terminal elimination half life of methadone? (D1 knowledge) a. 8 hours b. 12 hours c. 24 hours d. 40 hours 20. How important do you believe it is for a HPM physician to be able to assess risks to the patient prior to starting methadone?(d3 attitude) important

21. What monitoring instructions would you give the family caregiver for a patient starting methadone therapy? (D7 knowledge) 22. Which of the following is one of the mechanisms of action of methadone? Select all that apply. (D1 knowledge) a. Mu receptor agonist b. Kappa receptor anatagonist c. N methyl D aspartate receptor agonist d. N methyl D asparate receptor antagonist e. Inhibits reuptake of serotonin in CNS f. Inhibits reuptake of norepinephrine in CNS 23. List three medications known to be strong inducers of methadone metabolism. (D4 knowledge) a. Open answer 24. VB is an 84 year old woman with end stage dementia. She has multiple co morbid conditions including diabetes, dyslipidemia, seasonal allergies, hypertension, severe osteoarthritis in both hips and GERD. She has been exhibiting combative behavior that seems consistent with physical discomfort based on nonverbal cues. This behavior has not resolved with acetaminophen, and she is not a candidate for a NSAID, and other coanalgesics do not seem reasonable. She is not taking any medications known to interact with methadone, and she is opioid naïve. What dose of methadone would you recommend starting for VB? (D5 knowledge) 25. How accurately are you able to recommend doses to safely and accurately increase an opioid dose based on a patient s response to therapy? (D7 attitude) a. Not at all b. Slightly c. Somewhat d. Moderately e. Very well

26. KR is a 64 year old woman admitted to hospice with stage 4 esophageal cancer. Her pain is visceral in nature, and acetaminophen has not controlled her pain. She is not a candidate for a nonsteroidal anti inflammatory agent? She is not taking any medications known to interact with methadone, and she is opioid naïve. What dose of methadone would you recommend starting for KR? (D5 knowledge) 27. How skillfully are you able to identify appropriate and inappropriate patients for methadone therapy (as an analgesic)? (D2 skills) 28. WB is 48 year old man admitted to hospice with end stage AIDS. He is receiving transdermal fentanyl 50 mcg/h and oral morphine 20 mg every 2 hours as needed for pain (taking 1 2 doses per day). The only other medication he is taking is Kaletra and he refuses to discontinue therapy. He has a normal body habitus. You have decided to switch to methadone hoping to get an enhanced effect in treating his neuropathic pain. What methadone dose would you recommend to replace the transdermal fentanyl patch, and how would you time this transition (e.g., when do you remove transdermal fentanyl patch relative to starting methadone therapy)? (D6 knowledge) 29. How skillfully are you able to determine a starting dose of methadone in an opioidtolerant patient (e.g., perform a conversion calculation to methadone)? (D6 skill) 30. How important do you believe it is for you to be able to identify appropriate and inappropriate patients for methadone therapy (as an analgesic)? (D2 attitude) important

31. How skillfully are you able to determine a starting dose of methadone in an opioidnaïve patient? (D5 skill) 32. Which of the following scenarios is an example of an INAPPROPRIATE candidate for conversion to methadone therapy? (D2 knowledge) a. Patient lives alone but is mentally competent b. Patient is cognitively impaired but has a competent caregiver c. Patient is within days of death d. Patient expresses concern that methadone is for druggies 33. PR is a 62 year old man with end stage lung cancer. He is admitted to hospice on OxyContin 40 mg po q12h, and OxyIR 15 mg po q2h (takes about 3 doses per day). His pain control is fairly good but could be a bit better. He is receiving all appropriate coanalgesics, and he is not taking any medications that would interact with methadone. What regimen would you recommend if converting to methadone instead of OxyContin, and using morphine instead of oxycodone for breakthrough pain? (D6 knowledge) 34. Aside from the usual opioid induced adverse effects, risk factors for what potential adverse effect should be assessed prior to starting methadone therapy? (D3 knowledge) (cardiovascular QTc prolongation) 35. How important do you believe it is for you to be able to determine a starting dose of methadone in an opioid tolerant patient (e.g., perform a conversion calculation to methadone? (D6 attitude) important 36. What barriers, if any, exist to you prescribing and monitoring methadone therapy with greatest ease and competence? (e.g., lack of physical resources, lack of structure/process, information or knowledge deficit, no interest, no perceived value, etc.). (Gen)

37. How would you prefer to receive instruction and training in methadone prescribing and monitoring? a. Scheduled live lecture (e.g., one hour lecture, practice problems) to be conducted at an appointed time b. Asynchronous online learning (e.g., one hour pre recorded lecture, practice problems) to be completed as your schedule allows c. Assigned reading and practice problems